Cite
HARVARD Citation
Mills, A. et al. (n.d.). 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study. Open forum infectious diseases. pp. S186-S187. [Online].